Edwards Lifesciences
EW
101.85
-2.03
-1.95%
Edwards Lifesciences
US · EW
#442 by market cap
Listed 1970
101.85
-2.03
-1.95%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Company notice
Edwards Lifesciences | 4: Statement of changes in beneficial ownership of securities-Officer Zovighian Bernard JSEC · 2026/11/10
-
Rating change
BofA Securities Maintains Edwards Lifesciences(EW.US) With Buy RatingMarket Newswire · 2026/11/10
-
Rating change
Edwards Lifesciences Is Maintained at Buy by TD CowenDow Jones · 2026/11/12
-
Rating change
TD Cowen Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $121Market Newswire · 2026/11/11
-
Rating change
Edwards Lifesciences Price Target Raised to $121.00/Share From $117.00 by TD CowenDow Jones · 2026/11/12
-
Rating change
TD Cowen Initiates Edwards Lifesciences(EW.US) With Buy Rating, Announces Target Price $117Market Newswire · 2026/11/10
-
Rating change
Edwards Lifesciences Is Maintained at Overweight by Wells FargoDow Jones · 2026/11/16
-
Rating change
Wells Fargo Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $121Market Newswire · 2026/11/16
-
RBC Capital Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $115Market Newswire · 2026/11/20
-
Leerink Partners Adjusts Price Target on Edwards Lifesciences to $116 From $112MT Newswires · 2026/11/19
-
Rating change
Wells Fargo Adjusts Price Target on Edwards Lifesciences to $121 From $113MT Newswires · 2026/11/16
-
Company notice
Edwards Lifesciences | 144: Notice of proposed sale of securities pursuant to Rule 144SEC · 2026/11/11
-
Rating change
Daiwa Securities Adjusts Price Target on Edwards Lifesciences to $120 From $98MT Newswires · 2026/11/12
-
Leerink Partners Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $116Market Newswire · 2026/11/19
-
Company notice
Edwards Lifesciences | 4: Statement of changes in beneficial ownership of securities-Officer Dahl Andrew M.SEC · 2026/11/14
-
RBC Capital Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $115Market Newswire · 2026/11/20
-
Edwards Lifesciences' 2027 Guidance Seen Leaving Room for Upward Revisions, RBC SaysMT Newswires · 2026/11/21
-
Company notice
Edwards Lifesciences | 8-K: Current reportSEC · 2026/11/20
-
Rating change
TD Cowen Adjusts Price Target on Edwards Lifesciences to $121 From $117MT Newswires · 2026/11/11
-
Company notice
Edwards Lifesciences | 4: Statement of changes in beneficial ownership of securities-Officer Lippis Daniel J.SEC · 2026/11/11
-
Rating change
Edwards Lifesciences Is Maintained at Overweight by JP MorganDow Jones · 2026/11/6
-
Rating change
Edwards Lifesciences Is Maintained at Overweight by Wells FargoDow Jones · 2026/11/5
-
Rating change
Barclays Maintains Overweight on Edwards Lifesciences, Raises Price Target to $120Benzinga · 2026/11/6
-
A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $106 to $125Market Newswire · 2026/11/6
-
Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $117Benzinga · 2026/11/6
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.
Edwards Lifesciences discussion 0 comments